Semaglutide Injection Sites for Weight Loss | Clinical Guide

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide for weight loss is administered via subcutaneous injection once weekly, typically in the abdomen, thigh, or upper arm. Proper injection technique and site rotation minimize tissue irritation and support consistent medication absorption, a foundational element of effective GLP-1 therapy.

Beyond technique, understanding your individual metabolic and genetic context—including peptide pathway predispositions—can help frame more personalized discussions with your provider about dosing strategy and treatment adjustments. PlexusDx emphasizes precision-informed wellness grounded in clinical evidence.

Approved Subcutaneous Injection Sites and Anatomy Considerations

The FDA-approved injection sites for semaglutide include the abdomen (at least 2 inches from the navel), anterior and lateral thigh, and upper arm. Each site has different subcutaneous tissue thickness, which can influence absorption kinetics and local tolerability. Abdominal injection generally offers the most reliable absorption due to consistent subcutaneous depth.

Rotating injection sites reduces risk of lipohypertrophy (fatty tissue buildup) and injection-site reactions. Best practice involves using different body areas week to week and varying injection points within each area. Patients with higher baseline BMI may have anatomical advantages for abdominal injection due to increased subcutaneous depth.

Injection Site Rotation Framework and Tissue Health Optimization

Systematic site rotation protects tissue integrity and maintains consistent medication delivery. A structured approach minimizes local reactions such as erythema, bruising, and induration. The table below outlines a clinically recommended rotation pattern that cycles through approved anatomical regions.

Week	Preferred Site	Anatomical Details	Rotation Rationale
Week 1	Abdomen (left)	2+ inches from navel; 2–3 cm subcutaneous depth	Optimal absorption; predictable kinetics
Week 2	Thigh (right anterior)	Mid-thigh; 1.5–2 cm subcutaneous depth	Alternate major depot; monitor for bruising
Week 3	Upper arm (left)	Outer aspect; 1–1.5 cm subcutaneous depth	Smaller depot; useful for sensitivity assessment
Week 4	Abdomen (right)	Mirror of Week 1; consistent geometry	Return to primary site; allow 3–4-week healing

Technique, Needle Gauge, and Local Reaction Management

Standard semaglutide pens use 29-gauge, 6 mm needles designed for subcutaneous delivery. Proper technique includes pinching a skin fold, inserting the needle at a 90-degree angle, holding for 6 seconds post-injection, and withdrawing slowly to reduce tissue trauma. Hand hygiene and room-temperature medication improve tolerability.

Local reactions—including redness, swelling, bruising, and itching—are typically mild and transient. Rotating sites, applying ice pre-injection, and allowing adequate healing time between injections at the same location minimize these effects. Persistent or severe reactions warrant provider evaluation to rule out infection or hypersensitivity.

Biomarker Context and Individualized Dosing Considerations

While injection site selection is standardized, individual tolerance and efficacy may vary based on underlying metabolic and genetic factors. Baseline inflammatory markers, insulin sensitivity indices, and peptide pathway genetics can inform how a provider tailors the starting dose, titration schedule, and monitoring frequency. These contextual factors do not change injection technique but support more targeted treatment planning.

Providers may consider biomarker profiles when evaluating treatment response or managing side effects. For example, individuals with certain GLP1R or GIPR genetic variants may show differential response patterns, while inflammatory biomarkers may correlate with injection-site sensitivity. Discussing your health history, metabolic screening results, and family background helps providers optimize your semaglutide strategy from the outset.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in key GLP-1 and metabolic pathways—including GLP1R rs6923761, GIPR rs1800437, MC4R rs17782313, and FTO rs9939609—which may help provide context for how your body processes and tolerates GLP-1 medications. Understanding these variants can support more informed discussions about starting dose, titration pace, and expected response timeline.

The genetic test does not predict exact medication response or guarantee outcomes; rather, it identifies predispositions in peptide genetic pathways that should be interpreted with a qualified healthcare provider. Compounded semaglutide from PlexusDx (from licensed 503A pharmacies) combined with personalized biomarker and genetic context can support a more precision-informed approach to weight management.

When you combine baseline health assessment, biomarker insights, and genetic predispositions with proper injection technique and site rotation, you create a foundation for safer titration and early detection of individual tolerability patterns. This integrated approach can help your provider make more informed decisions about dosing adjustments and ongoing monitoring.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.